efmoroctocog alfa efmoroctocog alfa efmoroctocog alfa, sold under the brand name elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia a. efmoroctocog alfa is a recombinant human coagulation factor viii, fc fusion protein (rfviiifc). it is produced by recombinant dna technology in a human embryonic kidney (hek) cell line. efmoroctocog alfaclinical datatrade nameselocta, eloctateother namesantihemophilic factor (recombinant), fcfusion proteinlicense data eu ema: by inn us dailymed: eloctate pregnancycategory au: c routes ofadministrationintravenousdrug classantihemorrhagicatc codenonelegal statuslegal status au: unscheduled uk: pom (prescription only) us: ℞-only eu: rx-only identifierscas number1270012-79-7drugbankdb11607unii7pcm518ylrkeggd10830d10539chemical and physical dataformulac9736h14863n2591o2855s78molar mass216390.96 g·mol−1 it was approved for medical use in the united states in june 2014, and for use in the european union in november 2015. medical uses in the united states, efmoroctocog alfa (eloctate) is indicated for adults and children with hemophilia a for (1) on-demand treatment and control of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes. in the european union, efmoroctocog alfa (elocta) is indicated for treatment and prophylaxis of bleeding in people with haemophilia a.